<DOC>
	<DOCNO>NCT02760901</DOCNO>
	<brief_summary>Cisplatin major anti-neoplastic drug use treatment solid tumor . Its chief dose limit side effect nephrotoxicity . Twenty percent patient receive high-dose cisplatin undergo severe renal dysfunction . Acetazolamide N-acetylcysteine ( NAC ) ameliorate Cisplatin-induced nephrotoxicity rat . No study date evaluate protective effect acetazolamide NAC cisplatin nephrotoxicity human . Aim study evaluate effect acetazolamide NAC cisplatin nephrotoxicity human compare mannitol . Patients method . A total 52 patient receive standard hydration measure cisplatin randomize three group : 20 patient receive mannitol , 15 patient receive acetazolamide 17 patient receive NAC . Patients ` kidney function monitor use serum creatinine , creatinine clearance blood urea nitrogen ; kidney injury assess use RIFLE criterion . Patients ` liver function test hematological parameter also monitor .</brief_summary>
	<brief_title>Evaluation Effect Acetazolamide , Mannitol N-acetylcysteine Cisplatin-Induced Nephrotoxicity</brief_title>
	<detailed_description />
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Cancer patient receive cisplatin base chemotherapy protocol . 2 . Adult patient 18 65 year . 1 . Existing renal impairment ( Creatinine clearance &lt; 30 ml/minute ) 2 . Severe hepatic impairment ( Child Pugh score C ) . 3 . Hypersensitivity sulfonamides . 4 . Patients chronic noncongestive angle closure glaucoma . 5 . Hypersensitivity sulphur compound , Nacetylcysteine component formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>